Angelica Welch

Articles

Role of Surgery in Early Lung Cancer Remains Invaluable

October 25th 2018

Mark Widmann, MD, discusses the role of surgery in the treatment of patients with early-stage lung cancer.

Higher Dose of Ipilimumab Added to Nivolumab Effective in Bladder Cancer

October 22nd 2018

Extended follow-up data from the CheckMate-032 study shows a trend toward higher overall response and longer progression-free survival with the regimen of nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg in patients with platinum-pretreated metastatic urothelial carcinoma.

Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer

October 22nd 2018

The PARP inhibitor olaparib significantly improved progression-free survival as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.

Tepotinib Plus Gefitinib Improves PFS in MET+ EGFR-Mutant NSCLC

October 21st 2018

The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with MET mutated EGFR-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.

Adding Radium-223 to Abiraterone Shows No Survival Advantage in mCRPC

October 20th 2018

Adding radium-223 dichloride to abiraterone acetate and prednisone did not improve survival in patients with metastatic castration-resistant prostate cancer.

Gomella Gives Update on Nonmetastatic CRPC Advances

October 19th 2018

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses the shifting landscape of nonmetastastic CRPC, along with other developments across the prostate cancer paradigm.

Biosimilar Excitement Rooted in Cost Reduction

October 19th 2018

Ruth O’Regan, MD, discusses the excitement with biosimilars and the potential impact they could have on the US drug market.

Expert Breaks Down Diagnosis and Treatment of Classical MPNs

October 19th 2018

Vivian G. Oehler, MD, discusses the diagnosis, risk prognostication and therapeutic strategies for polycythemia vera, essential thrombocytopenia, and myelofibrosis.

Expert Discusses Emerging Treatments in Early Pancreatic Cancer

October 17th 2018

Afsaneh Barzi, MD, discusses updates in the treatment of patients with pancreatic cancer, as well as the importance of genetic testing.

I-SPY Trials Lead Investigator Discusses Successes and Goals

October 11th 2018

Laura J. Esserman, MD, MBA, discusses the goals of the I-SPY trials and their impact thus far on patients with high-risk early breast cancer.

FDA Panel Backs Rituximab Biosimilar

October 10th 2018

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 recommending approval of the rituximab biosimilar CT-P10 for 3 non-Hodgkin lymphoma indications.

Combination Trials Signal Next Wave of Treatment for CLL

October 9th 2018

Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia.

High-Dose Chemotherapy and ASCT Reign Supreme in Frontline Myeloma

October 8th 2018

Among new advances in multiple myeloma, high-dose chemotherapy and allogeneic stem cell transplant remain the go-to frontline treatment for patients with newly diagnosed multiple myeloma.

Allison Reflects on a Career in Immunology, Nobel Prize

October 4th 2018

James P. Allison, PhD, reflects on his research in immunology, the impact it has had on patients with cancer, and where the field is headed.

Treatment Discontinuation Achievable in Select Patients With CML

October 4th 2018

Ehab Atallah, MD, discusses the discontinuation of treatment for patients with chronic myeloid leukemia.

Cemiplimab Under Investigation in Cervical Cancer

October 3rd 2018

Krishnansu S. Tewari, MD, discusses the exploration of cemiplimab and the promise of immunotherapy in cervical cancer.

Approaching the Topic of Biosimilars With Patients

October 2nd 2018

Yelena Y. Janjigian, MD, discusses the reality of biosimilars entering the US market and how oncologists should approach discussing these agents with their patients.

CLL Landscape Continues to Expand With Addition of Venetoclax

October 1st 2018

Javier A. Pinilla-Ibarz, MD, PhD, discusses updates in the treatment of patients with chronic lymphocytic leukemia.

Molecular Testing, Immunotherapy To Be Highlighted at 20th Annual Breast Cancer Conference

September 29th 2018

Advances in subtype-specific treatments, immunotherapy, ongoing issues with younger patients, the optimal use of neoadjuvant and adjuvant regimens, and molecular testing will be discussed at the 20th Annual Lynn Sage Breast Cancer Symposium.

Genomics of Bladder Cancer Remain Largely Unknown

September 26th 2018

Joshua J. Meeks, MD, PhD, discusses the current understanding of genomics in bladder cancer.